Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281742 · ClinicalTrials.gov registry record · NA
Amblyopia Treatment for Children Aged 8 to 12 Years
A NA study of Amblyopia, sponsored by Retina Foundation of the Southwest.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07281742: Recruiting NA study of Amblyopia, sponsored by Retina Foundation of the Southwest.
NCT07281742 is a NA study of Amblyopia that is actively recruiting participants, run by Retina Foundation of the Southwest. The registered enrollment target is 30 participants, below the 164-participant average among 24 other Amblyopia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07281742, a NA study of Amblyopia, is actively recruiting participants, sponsored by Retina Foundation of the Southwest.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to assess the effect of at-home amblyopia treatment with Curesight™ for children aged 8 to 12 years. Curesight™ allows you to stream any videos on a computer screen at home but the amblyopic eye will see the entire screen clearly while part of the image will be blurred for the other eye. There is already a pivotal clinical trial showing that this treatment is effective for young children and Curesight™ has been cleared for use as an amblyopia treatment by the FDA for children as young as 4 years.
Primary Outcome
Change in logMAR best-corrected visual acuity of the amblyopic eye compared with baseline best-corrected visual acuity.
Conditions Studied
Interventions
- DEVICE Curesight dichoptic videos
Study Locations (1)
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT07281742 shows while recruiting
NCT07281742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 164-participant average among 24 other Amblyopia trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 1 intervention - of which Curesight dichoptic videos is the first listed.
NCT07281742 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07281742 about?
NCT07281742 is a clinical study titled "Amblyopia Treatment for Children Aged 8 to 12 Years". This study is being done to assess the effect of at-home amblyopia treatment with Curesight™ for children aged 8 to 12 years. Curesight™ allows you to stream any videos on a computer screen at home but the amblyopic eye will see the entire screen clearly while part of the image will be blurred for t...
What is the current status of trial NCT07281742?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-01-07. Estimated completion is 2028-06-30.
What conditions does trial NCT07281742 study?
This clinical trial studies the following conditions: Amblyopia.
What interventions are being tested in trial NCT07281742?
The interventions under investigation include: Curesight dichoptic videos (DEVICE).
Who is sponsoring clinical trial NCT07281742?
This trial is sponsored by Retina Foundation of the Southwest, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281742 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07281742's enrollment target sits among peer trials
30 21st of 24 higher than 3 of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Noninvasive Brain Stimulation in Adult Amblyopia
RECRUITING · NA
-
OCT Eccentric Fixation and Amblyopia in Children
RECRUITING · NA
-
Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games
RECRUITING · NA
-
Patch-free Occlusion Therapy
RECRUITING · NA
-
Novel Amblyopia Treatment With Virtual Reality Games
RECRUITING · NA
-
Binocular Amblyopia Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI